Grants for Public housing authorities - Food and Nutrition

This funding opportunity supports postdoctoral researchers in biomedical and behavioral fields, providing mentorship and resources to help them develop into independent scientists.

This funding opportunity provides financial support for researchers to quickly evaluate new policies or programs aimed at influencing behaviors related to obesity, such as diet and physical activity, to help prevent or reduce obesity rates.

This funding opportunity supports high-risk, multi-center observational studies aimed at advancing research on diabetes, digestive diseases, kidney disorders, and other related health conditions, encouraging diverse institutions to collaborate and innovate.

This funding opportunity provides financial support for research sites to study Type 1 diabetic nephropathy by recruiting patients, conducting kidney biopsies, and collecting data to identify new treatment targets and improve precision medicine approaches.

This grant provides funding to U.S. institutions to foster collaboration and support early-career researchers in benign urology through training, resource sharing, and professional development opportunities.

This funding opportunity supports a central coordinating center that will enhance collaboration and provide resources for research in nonmalignant hematology, particularly aimed at fostering the development of junior investigators and innovative projects across multiple institutions.

The "Chronic Pancreatitis Clinical Research Consortium (CPCRC)- Clinical Centers (CPCRC-CCs)" grant aims to fund ongoing studies on chronic pancreatitis and related conditions, with a focus on understanding the risk factors for pancreatic cancer in patients with chronic pancreatitis and newly diagnosed diabetes, by supporting a consortium of clinical centers and a data management center.

This funding opportunity supports U.S.-based organizations in conducting research to better understand and manage heart-related side effects of cancer treatments, with a focus on improving detection, monitoring, and data sharing.

The purpose of this funding opportunity announcement (FOA) is to support efficient natural history studies alone or in conjunction with the development and validation of clinical outcome assessments (COAs) and/or biomarker studies to address the unmet needs in rare neurodegenerative diseases for children and adults. Through the support of studies with high quality and interpretable data elements, FDA expects to address critical knowledge gaps, remove major barriers to progress in the field, exert a significant and broad impact on a specific rare neurodegenerative disease or multiple rare neurodegenerative diseases with similar pathophysiology, and facilitate rare disease product development.

This funding opportunity provides financial support for new and underrepresented researchers in the health sciences to conduct projects aligned with the missions of NIAID or NIDDK.

Under the Resilient Food Systems Infrastructure Program managed by the Pennsylvania Department of Agriculture (PDA) and funded by the USDA Agricultural Marketing Service (AMS), Simplified Equipment-Only Grants are designed to support Pennsylvania's food system transformation. These grants, focusing on equipment purchases for small to mid-size producers and processors, aim to diversify, distribute, and localize food systems to enhance consumer access, producer options, and rural community markets. Grant amounts range from $10,000 to $100,000, requiring no cost sharing. Eligible equipment expenses include purchase costs, delivery, and installation if included in the official bid. Applications are accepted electronically, with project completion required by June 30, 2026.

The U.S. Food and Drug Administration (FDA) seeks applications to develop, implement, and evaluate a human abuse potential (HAP) study of botanical Kratom. FDA has previously warned consumers about the use of Kratom (Mitragyna speciosa), a plant indigenous to Southeast Asia. Kratom alkaloids have demonstrated both affinity and activity at receptor sites known to be associated with abuse, such as mu opioid receptors. Although Kratom use is prevalent, to date, clinical evaluations of its abuse potential have been limited. The proposed HAP study should be performed in accordance with the guidance for industry, "Assessment of Abuse Potential of Drugs," including (but not limited to) the selection of an appropriate comparator(s) and outcome measures, statistical analyses etc. Interested parties, will also complete the submission of an Investigational New Drug (IND) application and obtain Institutional Review Board (IRB) clearance.

This grant provides funding for research aimed at understanding the factors that contribute to health disparities in HIV and aging among racial and ethnic minorities, low-income populations, and other underserved groups, focusing on how multiple health conditions affect their overall well-being and quality of life.

This program provides funding to individuals, businesses, and organizations in Missouri for projects that increase local food production and availability, particularly in areas facing food insecurity.

This funding opportunity supports high-risk, multi-center clinical trials aimed at addressing significant health issues related to diabetes, digestive diseases, and kidney disorders, encouraging diverse institutions to apply for impactful research that can transform clinical practices.

The purpose of this Notice of Funding Opportunity (NOFO) is to solicit research designed to capacitate, transform, and scale the delivery of HIV testing, prevention, and care services through pharmacists and pharmacies in US and/or global settings. This includes theadvancement of training curricula to enable pharmacy students, pharmacists, pharmacies, and pharmacy systems to deliver the spectrum of needed HIV services with ease, equity, and effectiveness. This NOFO uses the R21 grant mechanism, while RFA-MH-25-185 uses the R01 mechanism. Projects that lack preliminary data or that propose to pilot a novel intervention may be most appropriate for the R21 mechanism. Applications with preliminary data and those proposing large-scale clinical trials or longitudinal analyses should consider using the R01 mechanism.

Sodium-glucose co-transporter-2 inhibitors (SGLT2i) that were developed for the treatment of type 2 diabetes (T2D) have significant protective effects for cardiac and renal diseases for people with and without diabetes. However, SGLT2i are not currently approved for individuals with type 1 diabetes (T1D) and there is an increased risk of diabetic ketoacidosis (DKA) for this population. Despite this concern, these drugs are increasingly being prescribed off-label for people with T1D. Continuous ketone monitoring (CKM) is a rapidly evolving technology that could be utilized clinically to prevent DKA by an early warning of elevations in ketone levels.The purpose of this NOFO is to solicit applications for studies that will develop and test risk mitigation strategies that involve the clinical integration of CKM for the safe use of SGLT2i for people living with T1D so that they may benefit from the cardiac and renal protection and glucose-lowering effects of this drug class. The NOFO will support short-term, clinical trials to gain and disseminate knowledge on safety and glucose control with CKM and SGLT2i use.Possible topics include testing optimal insulin delivery in open and closed loop systems or multiple daily injections and developing clinical protocols to control or ameliorate elevated ketone levels in individuals with T1D who are receiving adjunct therapy with SGLT2i.

FDA announces the availability of fiscal year (FY) 2024 funds to support one or more projects to 1) collect antimicrobial use data from diverse animal sectors, including domestic livestock, poultry, companion animals (dogs, cats, and horses), and minor species (e.g., fish, sheep, goats, etc.) and 2) contribute to the development of data collection frameworks, including providing data and expertise as resources and a public-private partnership frameworks are established.This grant will support the continued advancement of FDA's initiatives to support antimicrobial stewardship in veterinary settings. It will also support the National Action Plan objectives to engage the animal health community and relevant stakeholders to advance strategies intended to improve understanding of antimicrobial use and foster antimicrobial stewardship in animal agriculture.

This funding supports institutions in developing training programs for predoctoral and postdoctoral researchers in biomedical and clinical fields, with a focus on enhancing diversity and preparing trainees for successful research careers.

This funding opportunity supports interdisciplinary research teams to explore how medical devices can effectively relieve chronic pain while minimizing addiction risks.